Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

UroGen Pharma (URGN) Debt Ratio (2022 - 2025)

UroGen Pharma's Debt Ratio history spans 4 years, with the latest figure at 0.61 for Q4 2025.

  • For Q4 2025, Debt Ratio rose 43.09% year-over-year to 0.61; the TTM value through Dec 2025 reached 0.61, up 43.09%, while the annual FY2025 figure was 0.61, 43.09% up from the prior year.
  • Debt Ratio reached 0.61 in Q4 2025 per URGN's latest filing, down from 0.66 in the prior quarter.
  • In the past five years, Debt Ratio ranged from a high of 1.03 in Q2 2023 to a low of 0.35 in Q2 2024.
  • Average Debt Ratio over 4 years is 0.57, with a median of 0.53 recorded in 2023.
  • Peak YoY movement for Debt Ratio: skyrocketed 111.58% in 2023, then crashed 66.33% in 2024.
  • A 4-year view of Debt Ratio shows it stood at 0.72 in 2022, then dropped by 23.15% to 0.55 in 2023, then decreased by 22.91% to 0.43 in 2024, then soared by 43.09% to 0.61 in 2025.
  • Per Business Quant, the three most recent readings for URGN's Debt Ratio are 0.61 (Q4 2025), 0.66 (Q3 2025), and 0.59 (Q2 2025).